Introduction In the setting of recurrent prostate cancer (PCa), awareness and understanding of clinical findings are essential for accurate imaging interpretation. Accordingly, this text will first address the principles of recurrent PCa management. Subsequently, the principles of recurrent PCa evaluation with computed tomography (CT), magnetic resonance imaging (MRI), transrectal ultrasound (TRUS), and TRUS-guided biopsy will be described. Nuclear medicine methods are reviewed in Chapter 11. Management principles of recurrent prostate cancer General principles Prostate cancer is usually suspected based on the detection of an abnormal serum prostate-specific antigen (PSA) value (≥4 ng/ml is the most commonly used criterion) and diagnosed by TRUS-guided systematic prostate biopsy . With systematic biopsy, one or more cores are obtained from each prostate sextant regardless of TRUS findings . Although optional additional cores can be obtained from regions that are abnormal on TRUS or other imaging modalities, image-guided biopsy is currently accepted only as an adjunct to systematic biopsy . Biopsy results are used to assign the Gleason grade . Digital rectal examination (DRE) findings are used to determine clinical tumor stage; however, due to earlier detection by PSA testing, PCa is now non-palpable in about two-thirds of patients and the clinical stage often underestimates the pathologic tumor stage [4, 5] (Table 12.1). Newly diagnosed PCa is designated as “primary” PCa and its treatment modalities are designated as “primary” treatments.
|Original language||English (US)|
|Title of host publication||Prostate Cancer|
|Publisher||Cambridge University Press|
|Number of pages||28|
|State||Published - Jan 1 2008|
ASJC Scopus subject areas